Rubicon Research Limited is a focused pharmaceutical formulations company distinguished by its singular and intense concentration on the highly regulated United States market. Driven by innovation, the company emphasizes robust research and development to expand its portfolio of specialty products and drug-device combinations, a strategy that has propelled remarkable financial performance.

Rubicon Research was the fastest-growing Indian pharmaceutical formulations company between Fiscals 2023 and 2025, achieving a total revenue CAGR of 75.89%. This rapid expansion is underpinned by its success in the US generic market, where it ranks among the top Indian players in terms of FDA Abbreviated New Drug Application (ANDA) approvals. With a high commercialization rate of its approved products and a clean US FDA compliance record since 2013, Rubicon Research is well-positioned to continue capturing market share through its disciplined, ROI-centric approach to product selection and development.

For the year/period ended (Rs. in Cr.)

For year/ period ended ( in Cr.)

*Market cap @upper band

• Exclusive US Market Focus and Growth: Rubicon Research is the fastest-growing peer, uniquely focusing completely on the US market, which generates over 98% of revenue.
• Superior Margin and Product Strategy: A data-driven product mix of new and specialty items allowed for 8.0% average price growth and consistent gross margins above 70% (FY22–FY25).
• Strong R&D and Pipeline: Significant R&D investment and a team of 170 scientists support a robust portfolio of 72 active ANDAs and 17 products awaiting US FDA approval.
• Robust Commercialization & Compliance: The Company utilizes established US distribution channels (including major wholesalers) and maintains a cost-effective Indian manufacturing base with a perfect US FDA compliance record.

The Company RUBICON RESEARCH LIMITED IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:

• Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by the Company (₹ 310 Cr.)
• Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes

At the upper band of IPO ₹ 485, the stock is valued at 59.44 P/E multiple. Hence, well-informed investors subscribe for medium to long term perspective.